Clearance of the non-permanent implant technology is backed by safety and efficacy results from the pivotal Expander-2 trial. On March 16, 2026, Prodeon Medical announced FDA 510(k) clearance for the ...
On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review. In this video, recorded at the 41st Annual Congress of the European Association of ...
The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy ...
Combining ¹⁷⁷Lu-rosopatamab tetraxetan with ARPIs or followed by docetaxel met primary safety/dosimetry objectives in a 36-patient international lead-in and supported feasibility within contemporary ...
The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and ...
Enzalutamide/leuprolide reduced metastasis or death versus leuprolide alone (HR 0.42) and improved overall survival (HR 0.597); enzalutamide monotherapy also improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results